IL-18Rβ Inhibitors
Chemical inhibitors of IL-18Rβ can impact its function through various biochemical pathways that are integral to the protein's role in inflammation and immune response. Acetyl-Salicylic Acid, by inhibiting cyclooxygenase enzymes, reduces the production of prostaglandins, which are key mediators of inflammation. This action can lead to a decrease in the inflammatory signals that would otherwise enhance the activation of IL-18Rβ. Similarly, Zileuton and Montelukast target the leukotriene pathway; Zileuton inhibits leukotriene synthesis, while Montelukast blocks leukotriene receptors. Both actions serve to dampen the inflammatory milieu that is conducive to the activation of IL-18Rβ. Likewise, Ruxolitinib and Tofacitinib, as JAK inhibitors, prevent the phosphorylation and activation of STAT proteins, a process that is crucial for IL-18Rβ signaling via the JAK-STAT pathway. This disruption can lead to the indirect inhibition of the pro-inflammatory responses mediated by IL-18Rβ.
Further down the line of inflammatory signaling, Apigenin, Curcumin, and Sulforaphane all inhibit the activation of NF-kB, a transcription factor that regulates the expression of various inflammatory cytokines. By curbing NF-kB activity, these chemicals can decrease the transcription of inflammatory mediators that are involved in pathways where IL-18Rβ is active, thus inhibiting its function. Methotrexate contributes to this effect by decreasing the proliferation of T-cells through the inhibition of dihydrofolate reductase, leading to reduced purine synthesis. This action can decrease the T-cell responses that IL-18Rβ is known to influence. Lastly, Sunitinib and Dasatinib, as broad-spectrum tyrosine kinase inhibitors, can suppress the activity of kinases involved in cytokine signaling pathways. By inhibiting these kinases, they could disrupt the signaling cascades upon which IL-18Rβ depends for its activation, hence inhibiting its functional activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Aspirin | 50-78-2 | sc-202471 sc-202471A | 5 g 50 g | $20.00 $42.00 | 4 | |
As an inhibitor of cyclooxygenase enzymes (COX-1 and COX-2), Acetyl-Salicylic Acid can reduce the production of prostaglandins. Prostaglandins are involved in inflammation, which is a process where IL-18Rβ has a role. By reducing inflammation, the activation of IL-18Rβ by its ligand IL-18 can be indirectly inhibited due to a decrease in the inflammatory response that IL-18 would otherwise exacerbate. | ||||||
Zileuton | 111406-87-2 | sc-204417 sc-204417A sc-204417B sc-204417C | 10 mg 50 mg 1 g 75 g | $84.00 $307.00 $369.00 $1254.00 | 8 | |
Zileuton, a 5-lipoxygenase inhibitor, reduces the synthesis of leukotrienes, which are eicosanoids that contribute to the inflammatory response. Since IL-18Rβ is implicated in promoting inflammation, inhibiting leukotriene synthesis can suppress the inflammatory signals that may activate IL-18Rβ. | ||||||
Montelukast Sodium | 151767-02-1 | sc-202231 sc-202231A sc-202231B | 10 mg 25 mg 250 mg | $51.00 $85.00 $161.00 | 5 | |
Montelukast is a leukotriene receptor antagonist that blocks the action of leukotrienes on their receptors. By blocking leukotriene receptors, Montelukast can indirectly inhibit the inflammatory pathways in which IL-18Rβ participates, thus reducing its functional activity. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that can interrupt the JAK-STAT signaling pathway. Since IL-18Rβ utilizes JAK-STAT for signal transduction upon activation, Ruxolitinib may indirectly inhibit IL-18Rβ function by preventing downstream signaling events. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $94.00 $213.00 | 33 | |
Methotrexate acts as a competitive inhibitor of dihydrofolate reductase, leading to decreased production of tetrahydrofolate and, subsequently, reduced synthesis of purines. This reduction in purines can decrease the proliferation of T-cells, which are part of the immune response where IL-18Rβ is involved, thus indirectly inhibiting the functional response of IL-18Rβ. | ||||||
Apigenin | 520-36-5 | sc-3529 sc-3529A sc-3529B sc-3529C sc-3529D sc-3529E sc-3529F | 5 mg 100 mg 1 g 5 g 25 g 100 g 1 kg | $33.00 $214.00 $734.00 $1151.00 $2348.00 $3127.00 $5208.00 | 22 | |
Apigenin is a flavone that has been shown to inhibit the activation of NF-kB, a transcription factor that regulates the expression of various inflammatory cytokines. The inhibition of NF-kB can dampen the inflammatory signaling pathways that involve IL-18Rβ, indirectly reducing its functional activity. | ||||||
Curcumin | 458-37-7 | sc-200509 sc-200509A sc-200509B sc-200509C sc-200509D sc-200509F sc-200509E | 1 g 5 g 25 g 100 g 250 g 1 kg 2.5 kg | $37.00 $69.00 $109.00 $218.00 $239.00 $879.00 $1968.00 | 47 | |
Curcumin has multiple targets but is known to also inhibit NF-kB activation. By inhibiting NF-kB, Curcumin can suppress the transcription of inflammatory cytokines and chemokines that would otherwise operate in conjunction with IL-18Rβ, thereby indirectly inhibiting its activity. | ||||||
D,L-Sulforaphane | 4478-93-7 | sc-207495A sc-207495B sc-207495C sc-207495 sc-207495E sc-207495D | 5 mg 10 mg 25 mg 1 g 10 g 250 mg | $153.00 $292.00 $489.00 $1325.00 $8465.00 $933.00 | 22 | |
Sulforaphane is known to inhibit NF-kB pathway activation. By reducing NF-kB activity, Sulforaphane can decrease the inflammatory signaling that would typically enhance the function of IL-18Rβ, resulting in its indirect functional inhibition. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Sunitinib, a receptor tyrosine kinase inhibitor, can suppress the activity of kinases that are involved in the signaling pathways of various growth factors and cytokines. If these pathways are involved in the activation of IL-18Rβ, then Sunitinib could indirectly inhibit its function by disrupting these signaling cascades. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor that can interfere with the activity of kinases involved in cytokine signaling pathways. By inhibiting these kinases, Dasatinib could indirectly reduce the functional activity of IL-18Rβ by blocking the signaling processes it depends on for activation. | ||||||